Literature DB >> 3593417

Correlation of apparent intrinsic clearances of simultaneously administered S (+) and d3R (-) hexobarbital in the rat.

M van der Graaff, N P Vermeulen, P H Hofman, D D Breimer.   

Abstract

Pseudoracemic hexobarbital (HB), consisting of equal molar fractions of S (+) HB and deuterium-labeled R (-) HB, d3 R (-) HB, was administered orally to rats in a dose of 50 mg/kg. Concentrations of both enantiomers in blood were measured by an enantioselective mass fragmentographic assay. Clearance data of S (+) HB and d3 R (-) HB were correlated in untreated rats, and in rats pretreated with 3-methylcholanthrene (MC), carbon tetrachloride (CCl4), and different doses of phenobarbital (PB). Although in the different groups some variation in the clearance ratio of S (+) HB over d3 R (-) HB was found, the clearance of S (+) HB was generally up to a factor of five higher than the clearance of d3 R (-) HB, except for the CCl4-treated rats. From the present data it can be tentatively concluded that S (+) HB and R (-) HB are metabolized by similar (PB-inducible) cytochrome P-450s in control and PB- and MC-pretreated rats and that clearance data obtained with racemic HB following different pretreatments may be employed as a reflection of (PB-inducible) cytochrome P-450 activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593417     DOI: 10.1016/0006-2952(87)90088-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  2 in total

1.  Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

Authors:  J H Schellens; J H van der Wart; M Danhof; E A van der Velde; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

2.  Mephenytoin stereoselective elimination in the rat: III. Stereoselective time course of induction during chronic hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.